مورد إلكتروني
Safety and Dose Escalation Study of Intravenous Zinc Supplementation in Pediatric Critical Illness.
| العنوان: | Safety and Dose Escalation Study of Intravenous Zinc Supplementation in Pediatric Critical Illness. |
|---|---|
| المؤلفون: | Cvijanovich, Natalie Z |
| المصدر: | JPEN. Journal of parenteral and enteral nutrition; vol 40, iss 6, 860-868; 0148-6071 |
| بيانات النشر: | eScholarship, University of California 2016-08-01 |
| تفاصيل مُضافة: | Cvijanovich, Natalie Z King, Janet C Flori, Heidi R Gildengorin, Ginny Vinks, Alexander A Wong, Hector R |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | BackgroundCritically ill children have low plasma zinc (pZn), correlating with organ failure. Since Zn influences inflammation, immune function, and glucose control, Zn supplementation is a plausible therapeutic modality. We sought to determine a safe dose of intravenous (IV) Zn to restore pZn in critically ill children.MethodsStepwise dose escalation study of IV Zn supplementation at a tertiary children's hospital. All children (<10 years) admitted to the pediatric intensive care unit with a Pediatric Risk of Mortality III score >5, or ≥1 new organ failure were eligible. After consent, patients were sequentially enrolled into 4 dosing groups: (1) no zinc, (2) Zn250: 250 mcg/kg/d ZnSO4, (3) Zn500: 500 mcg/kg/d ZnSO4, or (4) Zn750: 750 mcg/kg/d ZnSO4 ZnSO4 was administered 3 times daily for 7 days. pZn was measured at baseline, end of first ZnSO4 infusion, 1 hour postinfusion, and 7 hours postinfusion on day 1, then daily through days 2-7. Interleukin-6 (IL-6), C-reactive protein (CRP), and lymphocyte subsets were measured on days 1 and 3. Glucose was measured 3 times daily for 7 days.ResultsTwenty-four patients were enrolled. Baseline demographics were similar among groups. Baseline pZn was low in all patients (mean [SD], 41.8 [16.0] mcg/dL). pZn increased over the study period in supplemented groups; however, mean pZn in the Zn750 group exceeded the 50th percentile. pZn was not associated with IL-6, CRP, or lymphocyte subsets among groups. Degree of hyperglycemia did not differ among groups. No patient had a study-related adverse event.ConclusionsIV zinc supplementation at 500 mcg/kg/d restores pZn to near the 50th percentile and is well tolerated. |
| مصطلحات الفهرس: | Humans, Critical Illness, Zinc, Prospective Studies, Pediatrics, Dose-Response Relationship, Drug, Dietary Supplements, Child, Preschool, Infant, Intensive Care Units, Pediatric, Female, Male, Administration, Intravenous, critical illness, hyperglycemia, inflammation, lymphopenia, pediatrics, zinc, Clinical Research, Clinical Trials and Supportive Activities, Nutrition, Patient Safety, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Medical and Health Sciences, Nutrition & Dietetics, article |
| URL: | |
| الإتاحة: | Open access content. Open access content public |
| ملاحظة: | application/pdf JPEN. Journal of parenteral and enteral nutrition vol 40, iss 6, 860-868 0148-6071 |
| أرقام أخرى: | CDLER oai:escholarship.org:ark:/13030/qt3mn6928q qt3mn6928q https://escholarship.org/uc/item/3mn6928qTest https://escholarship.orgTest/ 1391605525 |
| المصدر المساهم: | UC MASS DIGITIZATION From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1391605525 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |